A biological model of scabies infection dynamics and treatment explains
  why mass drug administration does not lead to elimination by Lydeamore, M. et al.
ar
X
iv
:1
61
2.
03
54
1v
1 
 [q
-b
io.
PE
]  
12
 D
ec
 20
16
A biological model of scabies infection dynamics and
treatment explains why mass drug administration does
not lead to elimination.
M. Lydeamorea,b, P.T. Campbellf,c,b, D.G. Regand, S.Y.C. Tongf,e,
R. Andrewse, A.C. Steerb, L. Romanid, J.M. Kaldord, J. McVernonf,c,b,
J.M. McCawa,c,b,∗
aSchool of Mathematics and Statistics, The University of Melbourne
bMurdoch Childrens Research Institute, The Royal Children’s Hospital, Melbourne
cMelbourne School of Population and Global Health, The University of Melbourne
dKirby Institute, UNSW Australia
eMenzies School of Health Research, Charles Darwin University
fPeter Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital and
The University of Melbourne
Abstract
Despite a low global prevalence, infections with Sarcoptes scabiei, or scabies,
are still common in remote communities such as in northern Australia and the
Solomon Islands. Mass drug administration (MDA) has been utilised in these
communities, and although prevalence drops substantially initially, these reduc-
tions have not been sustained. We develop a compartmental model of scabies
infection dynamics and incorporate both ovicidal and non-ovicidal treatment
regimes. By including the dynamics of mass drug administration, we are able
to reproduce the phenomena of an initial reduction in prevalence, followed by
the recrudescence of infection levels in the population. We show that even
under a ‘perfect’ two-round MDA, eradication of scabies under a non-ovicidal
treatment scheme is almost impossible. We then go on to consider how the prob-
ability of elimination varies with the number of treatment rounds delivered in
an MDA. We find that even with infeasibly large numbers of treatment rounds,
elimination remains challenging.
1. Introduction
Infections with the mite Sarcoptes scabiei, commonly known as scabies, are
relative uncommon in urban, well-developed environments. However, in many
lower income settings, particularly in tropical regions, scabies remains endemic.
In remote communities in northern Australia, for example, prevalence is as
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high as 49%, and in the Solomon Islands and Fiji, prevalence is 43% and 28%,
respectively[18]. Scabies is highly contagious, and causes intense itching on the
host [15]. Besides the psychological impact due to the constant itching [10], the
scratching leads to a break in the skin layer, creating a pathway for secondary
skin infections such as Group A Streptococcus (GAS) to take hold [6]. It has
been hypothesized that controlling scabies infections could lead to a reduction in
the disease burden attributable to GAS and its sequelae [6]. However, despite
multiple trials confirming the short term effectiveness of scabicidal therapies,
follow up studies in several communities have shown recrudescence of infection
within months to years of treatment cessation [14, 2, 23, 12].
Mathematical models provide useful frameworks in which to consider the
drivers of infectious disease, with a view to optimising treatment approaches.
To our knowledge, there exist only two models for scabies infection in humans
[4, 9], and neither of these models attempts to capture the natural history
of the mite’s life cycle in relation to the host. This omission is important
in understanding intervention effects, as the parasite’s life state can interact
critically with treatment success or failure.
Here, we develop a model of scabies infection and use it to explore the likely
impact of mass drug administration treatment strategies. The structure of this
paper is as follows: In Section 2, we summarise the biology of the mite and
the effect of ovicidal and non-ovicidal treatments. In Section 3, we develop and
introduce a compartmental model for scabies, including the effects of different
treatment mechanisms. In Section 4, the results of the investigation into the
model are presented, and in Section 5, the implications of our investigation are
discussed and summarised.
2. Scabies Biology and Treatment
The scabies mite progresses through three general life stages: egg, young
mite and adult. The eggs are relatively well studied, and are believed to take
approximately two days to hatch [3, 22, 7]. The young mite stage is more
complex, comprising a number of developmental stages. Initially, mites are
considered larvae, and are unlikely to emerge from the burrow in which the eggs
were laid. Mites remain as larvae for approximately five days [3, 22], before
developing into Protonymphs and Tritonymphs [3, 7]. In both of the nymph
stages, the mites roam about the body [16]. Finally, the nymphs develop into
adult mites, form breeding pairs, and the pregnant female mite lays eggs. The
second generation of adult mites appear after approximately 30 days of initial
infestation [16]. As it takes approximately five days for the nymphs to become
adults [3, 7], it follows that it must take approximately two weeks for an adult
mite to find a mate.
Consider the infestation cycle of an individual human host. An individual is
initially infected with an already impregnated mite. The pregnant mites begin
tunneling almost immediately once transferred [20], and lay 2-3 eggs per day.
These eggs hatch, and eventually develop into adult mites, completing the cycle
of infestation.
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In an individual’s first infection, a long asymptomatic phase is experienced,
lasting for up to 60 days [16]. In subsequent infections, the onset of itching is
almost instantaneous due to prior sensitisation, and the mite count is demon-
strably lower.
In the absence of treatment, little is known about natural recovery. In human
experiments, however, no individuals saw natural recovery after being infected
for almost 200 days [16].
As the infestation can only begin with a pregnant mite (we discount the
logical possibility that the host has a male and non-pregnant female transferred
to them and that they subsequently mate), we assume that an individual is only
infectious if they are harboring pregnant mites.
There are three widely-used treatments for scabies: Permethrin, Benzyl Ben-
zoate and Ivermectin. Permethrin and Benzyl Benzoate are a topical creams
which must be applied to the whole body for at least eight hours, a require-
ment associated with poor compliance [21]. Ivermectin is administered as a
single oral dose, leading to improved compliance. A key difference between the
treatments is that Permethrin and Benzyl Benzoate are believed to be ovici-
dal (egg-killing), and thus only one treatment may be necessary for clearance
[6, 21]. In contrast, Ivermectin is believed to be non-ovicidal, and so at least
two treatments are required to eliminate all the stages of the mite. In fact, two
doses of Ivermectin have been shown to significantly increase the probability
of clearance, when compared with a single dose [21]. Generally, in the absence
of a second non-ovicidal treatment, endogenous or continuing self-reinfection is
inevitable.
Consider again the infestation cycle of an individual. In the event of an
infested individual receiving a 100% effective non-ovicidal treatment, only the
eggs will remain on the individual. The eggs will inevitably hatch into larvae,
and, in the absence of a second treatment, eventually develop into adults, con-
tinuing the cycle of infestation. To clear the infestation successfully, a second
treatment will be required before the new generation of hatched mites begins
to lay eggs.
Although no natural recovery from primary scabies infections was observed
in human studies, a reduced level of infestation was observed in subsequent in-
fections, suggestive of some degree of immune-mediated suppression [16]. More-
over, in ‘real world’ settings, continuous background treatment of scabies occurs
through public health clinics as cases are identified. In areas with endemic infec-
tion, this background treatment may occasionally be supplemented through a
mass drug administration (MDA) using either an ovicidal or non-ovicidal treat-
ment regime.
3. Model Development
We introduce a compartmental mathematical model to characterise scabies
transmission and treatment in a population with high endemic prevalence, and
capture the potential differences between ovicidal and non-ovicidal treatments.
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βI γ
σ
Figure 1: The most basic scabies model. The probability of contact and infectiousness is
represented by β, the sexual maturity by γ and the time to eggs hatching by σ. The total
number of infectious individuals is given by I = XI + XIˆ . The solid arrows represent the
transitions that occur naturally, while the dashed arrows represent the effect of a treatment
event.
First, we develop the model considering the non-ovicidal treatment regime,
which does not kill the eggs laid by the mite. Later we will consider the model
including ovicidal treatment.
In addition to susceptible and infectious states, a population level model of
scabies with sufficient biological fidelity to study how an MDA impacts upon
the population must also consider a number of other states. As non-ovicidal
treatment for scabies kills living mites, but not the eggs of the mite, it is essential
to keep track of the the proportion of the population with only eggs, as in the
absence of a second treatment course, endogenous reinfection upon hatching
is inevitable. Given that the maturation time of the mite is notably longer
than the amount of time it takes the eggs to hatch, these life stages can be
considered mutually exclusive. As such, individuals in a population can be
broadly categorised into one of four mutually exclusive states: Susceptible (S),
Infectious (I), Infectious and with eggs present (Iˆ), and having only eggs (Gˆ).
Throughout, we use a hat ( ˆ ) to signify states with eggs present. A non-
ovicidal treatment will move an infectious individual from I to S, or from Iˆ to
Gˆ, depending on whether or not the individual currently has eggs present. Left
untreated, all modelled individuals will eventually reside in the Iˆ class, having
both living mites and eggs. The transitions of this system as a Markov chain
are given in Equations (A.1-A.5), and are represented by Figure 1. This model
accounts for eggs using the Iˆ and Gˆ states, and also accounts for the fact that
non-ovicidal treatment only kills the live mites, leaving eggs.
However, this model does not explicitly account for the sexual maturation
of the mite. This omission leads to two issues: firstly, the model implies that
as soon as any mite hatches on an individual who was only harboring eggs,
the individual is now harboring a mature, fertile adult mite. In reality, this
is not the case, as newborn mites undergo a period of sexual maturation and
development. Secondly, as an individual is harboring pregnant mites as soon as
an egg hatches, the period of time until new eggs are laid is small, and so the
likelihood of a successful second treatment resulting in total clearance of the
mites is negligible.
The maturation of the mite is modelled through the introduction of two new
states, Y and Yˆ , and is represented in Figure 2. Continuing the notation used
thus far, the Y state represents individuals who have only young mites, and
4
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Figure 2: A scabies model incorporating the life cycle of the mite. The parameter δ represents
rate at which an individual progresses from having only young mites to having at least one
mature mite, while 1/ρ represents how long until all mites hatch. The total number of
infectious individuals is given by I = XI +XIˆ
.
no eggs, while the Yˆ state represents individuals who have young mites with
eggs. Now, the likelihood of a successful second treatment has increased, as
individuals are ‘egg-free’ while in both the I and Y states. However, an early
second treatment will not clear infestation, as individuals may still be carrying
unhatched eggs (state Yˆ ). Despite these improvements, the model does not cap-
ture any difference in relative susceptibility for subsequent infections, differences
in host response between the first and subsequent infections including possible
changes in relative infectiousness, nor distinguish endogenous from exogenous
reinfection, all of which are well established phenomena of scabies infection as
discussed in Section 2. Also, this model does not consider the time it takes
mites to find an appropriate partner and mate once sexually mature.
These features are included in our full model (Figure 3). An asymptomatic
period has been introduced after the first infection (denoted by the IA and
IˆA states). We assume that repeated asymptomatic infections are unlikely,
except in the instance of very early treatment. Therefore, treatment from the
IˆA state is similar to that for any other stage of infection, transitioning to state
Gˆ under a non-ovicidal treatment scheme. Further, secondary infections have
been separated into two states. Continuing, or endogenous reinfection progresses
first through an adult mite state (M), and then through Ic2 and Iˆ
c
2 , while new
or exogenous reinfection occurs through I2 and Iˆ2. This model includes all
the biologically relevant features of the mite identified in Section 2, including
maturation and the production of eggs.
The model can be considered as a continuous-time Markov chain, with state
space,
Ω = {S, IA, IˆA, Iˆ , Gˆ, Yˆ , Y,M, S2, I
c
2 , Iˆ
c
2 , I2, Iˆ2}. (1)
Let the number of individuals in state i ∈ Ω at time t be Xi(t), and X(t) =
{Xi(t)}. All events then correspond to removing an individual from a given state
and placing a new individual in the destination state; thus, the total number
of individuals in the population remains fixed. For simplicity, we suppress the
explicit dependence on time from the state of the Markov chain. For example,
an initial infection event from the state S to the state IA is given by the state
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(a) Non-ovicidal treatment (b) Ovicidal treatment
Figure 3: A scabies model incorporating the life cycle of the mite, a subsequent infection
phase, and tracking exogenous and endogenous infections separately with (a) non-ovicidal
treatment and (b) ovicidal treatment. The expression for I is given in Equation (2). The
parameter ψ represents the rate at which symptoms to develop, and φ represents the relative
susceptibility for subsequent infections. The grey states in (b) are inaccessible for realistic
initial conditions.
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transition,
(XS , XIA)→ (XS − 1, XIA + 1) .
The dynamics of the model can be divided into two sections — the natural
transitions and the treatment transitions.
3.1. Natural Transitions
The natural transitions of the model consist of all the transitions which
occur without any treatment or intervention. We assume that the population
mixes homogeneously, and that contact rates are frequency dependent. Thus,
the initial infection transition,
(XS , XIA)→ (XS − 1, XIA + 1) ,
occurs at rate
β
N − 1
XSI(t),
where N is the number of individuals in the population and
I(t) = XIA +XIˆA +XIˆ +XI
c
2
+X
Iˆc
2
+XI2 +XIˆ2 , (2)
is the total number of infectious individuals at time t. Similarly, for subsequent
exogenous infections, the transition is,
(XS2 , XI2)→ (XS2 − 1, XI2 + 1) ,
which occurs at rate
φβ
N − 1
XS2I(t),
where φ ∈ [0, 1] is the relative susceptibility to secondary infections.
The transition from having pregnant mites only to adult mites and eggs
(XI → XIˆ) occurs at the rate at which adult mites lay eggs, γ. The per-
individual rate of developing symptoms is given by ψ. The per-individual rate
for eggs to begin hatching is given by σ, and the per-individual rate until all
eggs have hatched (once one has hatched) is given by ρ. The rate at which
the mites have completed development and become adults is δ, and the rate at
which these mites form breeding pairs is α.
Finally, the model allows for human population turnover through births and
deaths. All new births enter the S class, while the per-capita death rate out of
each class is given by µ, independent of disease status. Throughout, we assume
that births and deaths are balanced.
3.2. Treatment Transitions
Continuous background treatment is modelled using a constant per-individual
rate, τ . Mass drug administration starting at time t¯, whereby treatments are
distributed at a fixed rate for a specified period of time, [t¯, t¯ + κ), is modelled
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as a constant (not per-individual) rate out of each infected class. This rate is
given by,
ωXi(t) =
{
ηXi(t¯)
κ
I{Xi ≥ 0}, for t ∈ [t¯, t¯+ κ)
0, otherwise
for each infected state, where η ∈ [0, 1] is the effective coverage of the MDA,
incorporating both population coverage and efficacy, and κ is the duration of
the MDA. This rate is combined with an indicator function, I{Xi ≥ 0}, in
order to ensure each Xi(t) ≥ 0. An MDA treatment rate of this form ensures
that the expected number of individuals treated over the period of the MDA is
equal to the effective coverage of the MDA multiplied by the number of infected
individuals when the MDA is commenced.
Consider firstly treatment which is non-ovicidal. The dynamics of this treat-
ment are depicted in Figure 3 (a) with the dotted arrows. For individuals who
have both eggs and mites, the first treatment will move individuals to the eggs
only state, Gˆ, while an optimally timed second treatment would move an indi-
vidual to the S2 state (from state Y,M or I
c
2). Treatment at a non-optimal time
may simply move an individual straight back to the Gˆ state (from state Yˆ if too
early; or from Iˆc2 if too late), and so it is important to consider the time between
interventions, or the intervention interval, for non-ovicidal scabies treatments.
Comparatively, if treatment were ovicidal (Figure 3 (b)), then the desti-
nation state for each treatment event will be state S2, except from the state
IA, for which S remains the destination due to an assumption of no acquisi-
tion of immunity while experiencing asymptomatic infection. It is worth noting
that under an ovicidal treatment scheme, the states Gˆ, Yˆ , Y,M, Ic2 and Iˆ
c
2 , are
ephemeral, and so play no role in the equilibrium solutions of the system.
The size of the state space, |Ω|, is prohibitively large to allow numerical
solutions to the forward equations to be found for anything but small values
of N . However, the process may be simulated using the so-called Gillespie
algorithm [8]. The mean behaviour of the process can be explored using a
(deterministic) mean-field approximation. The full mean-field approximation,
x(t), is detailed in Appendix B.
We use the ode45 routine in MATLAB to calculate numerical solutions for
this mean-field approximation. The parameter values used for this work are
detailed in Table 1, with further details provided in Appendix C. Many of the
values relating to the natural history of the mite have been determined from
laboratory experiments [3], with the exception of the mean time for a mite to lay
eggs, which is controlled by the parameter γ. We choose γ based on estimates
for the mean time to the second generation of mites appearing post-infection
[16].
3.3. Objective Function
In order to determine optimal intervention intervals, we formulate a mathe-
matical optimisation problem. The objective function is chosen to be the mini-
mum proportion of the population who are carrying eggs over the time period
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Parameter Meaning Value−1 (days) Reference Notes
β Probability of contact and infectiousness 63 [11], [18]
φ Relative susceptibility to subsequent infections 0.5 Entire range of φ ∈ [0, 1] explored in Appendix D
α Rate of mating 15 [16]
γ Rate of egg laying 0.5 [20]
ψ Rate of symptoms developing 30 [16]
σ Rate of egg hatching 2 [3]
ρ Rate for mites to become nymphs 5 [3]
δ Rate of maturation 5 [3]
τ Rate of background treatment (non-ovicidal) 57.13 [11] Detailed in Appendix C
(ovicidal) 173.7 [11] Detailed in Appendix C
µ Death rate 18250 50 year life expectancy
Table 1: Parameter values (presented as the inverse) used in the model. All parameters are given in days.
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of interest. That is,
minimize
t1...tn
min(e(t))
subject to 0 < t1 < · · · < tn,
(3)
where,
e(t) = x
IˆA
+ x
Iˆ
+ x
Gˆ
+ x
Yˆ
+ x
Iˆc
2
+ x
Iˆ2
is the proportion of the population who have eggs at time t, and t1, . . . , tn are
the times at which a treatment round in the MDA occurs.
The first intervention time, t1, is entirely arbitrary, so in practice we fix t1
and the remaining intervention times, t2, . . . , tn are determined. Solutions are
calculated numerically using the fmincon routine in MATLAB.
Note that the problem stated in Equation (3) utilises the mean-field approxi-
mation, x(t). However, the same solution could also be obtained by formulating
the problem using the mean of the Markov chain, E[X(t)], as the only difference
between the problem formulations is the constant 1/N .
4. Results
First, we establish the equilibrium dynamics in the absence of an MDA.
Using the mean-field approximation, the model can be divided into three classes:
susceptible, infected and latent. The susceptible class consists of the states S
and S2, while the infected class consists of Ω\{S, S2, Gˆ}. Note that we make
an important distinction between an infected and an infectious state. Only
individuals who are harboring pregnant mites, and thus in states I, Iˆ, Ic2 , Iˆ
c
2 , I2
and Iˆ2 are classified as infectious. Individuals who are harboring any mites
are considered infected. That is, all infectious states as well as states Y, Yˆ and
M are considered infected. The latent class consists of only the Gˆ state, as
left untreated, individuals will inevitably progress to be infected. However, the
Gˆ state is an untreatable latent state under a non-ovicidal treatment scheme,
which is different to the latent phases incorporated into other disease models
[1, 13]. These three classes form SIS-like dynamics, as shown in Figure 4.
Before studying the actions of mass drug administration, we provide numer-
ical justification for the mean-field approximation, x(t), to the Markov chain,
X(t). Figure 5 shows that the system of ordinary differential equations given
in Appendix B approximates the mean behaviour of the system well, even in
the event of an MDA. As such, we will focus primarily on the results from the
mean-field approximation.
Having established non-MDA equilibria and the utility of the mean-field
approximation, we now investigate the impact of interventions on the system.
One crucial parameter here is the proportion of the infected population who
are successfully treated during a mass drug administration, η. For the purpose
of exploring model behaviour under an MDA with non-ovicidal treatment, we
assume that 100% of the population is treated 100% effectively. While this is
not achievable in practice, this provides a theoretical best-case scenario for an
MDA.
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Figure 4: Overall dynamics of the system including background treatment before reaching
equilibrium using the parameters in Table 1.
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Figure 5: 50 realisations of the Markov model (grey lines), using the Gillespie algorithm,
compared with the mean-field approximation (black dotted line) with two optimally timed
non-ovicidal interventions on (a) the proportion of infected individuals and (b) the proportion
of the population with eggs, using the parameters in Table 1.
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Figure 6: Impact of varying inter-intervention intervals for a 100% effective MDA using a
non-ovicidal treatment, using the parameter values in Table 1, for an MDA with two rounds
of treatment.
4.1. Intervention Intervals
Recall that when considering non-ovicidal interventions, it is clear that at
least two treatments are needed. We investigate the impact of the time between
these treatments in the event of an MDA. A local minimum for the optimisa-
tion problem in Equation (3) is identified in Figure 6. If the second treatment
occurs too early, then not all the eggs will have hatched (state X
Yˆ
), leading to
endogenous reinfection, while if the treatment occurs late, newly hatched mites
will have matured, mated and produced new eggs (state X
Iˆc
2
). Solving the op-
timisation problem numerically using the MATLAB routine fmincon gives an
optimal intervention interval of 13.94 days.
This intervention interval is closely linked to the modelled life-cycle of the
mite. With the parameter values in Table 1, the mean time to adult mites
reappearing (assuming no second treatment occurs) is 12 days. Intuitively, the
inter-intervention interval should be long enough so that all of the previous
eggs have hatched, but short enough so that the number of individuals infested
with eggs is small. This aligns closely with the calculated optimal intervention
interval of approximately 14 days.
Returning to Figure 5, it shows the dynamics of the system using two opti-
mally timed MDA interventions using a non-ovicidal treatment. It is clear that
even with an MDA which is maximally effective, two doses is not sufficient for
eradication of scabies from the population. In less than one year, prevalence
increases above 5% and after approximately 10 years (not pictured) the preva-
lence has returned to baseline levels. Even though the prevalence of infectious
individuals was reduced to very low levels (Figure 5 (a)), the proportion of the
population with eggs remains high (Figure 5 (b)), and so endogenous reinfection
and rebound is inevitable.
Having demonstrated that two non-ovicidal interventions is not sufficient for
eradication of scabies in this model, we now consider how many interventions
would be required for eradication with non-ovicidal treatment. Figure 7 shows
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Figure 7: Mean, x¯, of 1000 simulations of the Markov chain, X(t), and 95% confidence
intervals (calculated as x¯ ± 1.96 × s/
√
N , where s is the standard deviation of the sample)
which experienced die-out for varying numbers of successive optimally timed non-ovicidal
MDA treatments, using the parameter values in Table 1 and a population size of N = 2000.
the proportion of 1000 Gillespie simulations which resulted in eradication of
scabies for a population size of N = 2000 (a typical size for a high-prevalence
community in Northern Australia). In the case of having ten optimally timed in-
terventions inside the MDA, 93%(±0.8%) of the simulations showed eradication
of scabies. This further demonstrates the difficulties with achieving eradication
of scabies using a non-ovicidal treatment. Even with ten optimally timed in-
terventions, which would require drastically more resources than are currently
available, eradication is by no means guaranteed. These results have been gen-
erated under the assumption that the relative susceptibility to secondary in-
fections, φ = 0.5 (1). Appendix D shows that these findings are robust to
alternative assumptions on the level of relative susceptibility to secondary in-
fections, φ.
4.2. Mass Drug Administration with an ovicidal treatment
Thus far, we have considered only non-ovicidal treatment for scabies. Figure
3 (b) represents the dynamics using an ovicidal treatment. We now investigate
the effects of an MDA using an ovicidal treatment.
When using an ovicidal treatment with the parameters in Table 1, the preva-
lence of scabies is zero under only background treatment (using τ = 1/57.13)
due to the increased effectiveness of this treatment and assumed coverage level.
Accordingly, we recalibrate the model to give the same endemic prevalence as
used in our non-ovicidal example of 28%, achieved by setting τ = 1/173.7.
Clearly, a maximally effective (i.e. 100% coverage, 100% effective) MDA
for an ovicidal treatment will eradicate infection in the population. Figure 8
(a) shows how variation in the coverage of an MDA influences the outcome.
Note that coverage and compliance are confounded in our model. Unsurpris-
ingly, between the extremes, the minimum proportion of infected individuals is
monotonically decreasing.
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Figure 8: (a) Comparison of the coverage of an MDA using an ovicidal treatment on the
minimum proportion of infected individuals achieved and (b) impact of varying the inter-
intervention interval using an ovicidal treatment on the minimum proportion of the population
that has eggs using the parameter values in Table 1, and τ = 1/173.7 and an MDA effective
coverage of η = 0.7.
Choosing an MDA coverage of 70% and allowing for a second round of mass
drug administration, Figure 8 (b) shows the minimum proportion of the popu-
lation who are carrying eggs as a function of the interval between treatments.
This result suggests a ‘sooner is better’ approach to a follow up round of MDA
when using an ovicidal treatment scheme. However, we emphasise this result
arises from coverage and compliance being subsumed into the same measure and
so all individuals are assumed to be equally likely to be administered treatment
in the second course.
5. Discussion
We have developed a biologically informed mathematical model of scabies
infestations in a population which explicitly accounts for the multiple life stages
of the mite and the presence of eggs. While there have been other models of
scabies proposed [4, 9], they have not adequately captured the critical features
of the life-cycle of the mite. This model has provided a framework with which to
explore the different consequences of ovicidal and non-ovicidal treatment strate-
gies. Crucially, the model is able to qualitatively reproduce the recrudescence
of infection post mass drug administration that has been observed in practice
[5, 6], despite the prevalence of scabies becoming very small.
Our analysis has demonstrated that even under the assumption of 100%
coverage and efficacy for a non-ovicidal treatment, rebound of infection levels
is inevitable. Comparatively, a single dose of an ovicidal treatment with full
compliance and effectiveness is sufficient to eradicate infection. In the event of
an MDA with a non-ovicidal treatment, we have shown that the intervention
interval should be approximately two weeks, a number a closely linked to the
life-cycle of the mite.
Furthermore, when considering the effective coverage with ovicidal treat-
ment, we demonstrated that the relationship between effective coverage and
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short-term success is monotonic. If the issue with ovicidal drugs is one of compli-
ance, then it is a clear limitation of this model that compliant and non-compliant
individuals are not separated. This results in ovicidal treatment impact being
generally overestimated.
The model formulated here forms a basis for modelling scabies infection
in a population, but is by no means exhaustive. For example, we have not
considered reduced levels of infectiousness for subsequent infections or any form
of immunity. These features could potentially be included alongside an age
structured model once data becomes available [17, 19].
This model has provided the first mathematical insight into the limited long-
term success of MDA treatment of scabies in areas of endemic prevalence. By
using biologically relevant parameters, best-case MDA scenarios and issues sur-
rounding compliance have been explored, demonstrating the difficulty that is
associated with control of this infection.
6. Acknowledgements
M. Lydeamore is supported by an Australian Postgraduate Award; J. McVer-
non is supported by an NHMRC Career Development Fellowship (CDF1061321);
J. M. McCaw is supported by an ARC Future Fellowship (FT110100250). D. Re-
gan is supported by an NHMRC Program Grant (APP1071269); S. Y. C. Tong
is supported by an NHMRC Career Development Fellowship (CDF1065736); We
thank the NHMRC Centre for Research Excellence in Infectious Diseases Mod-
elling to Inform Public Health Policy (1078068). This work is supported by an
NHMRC Project Grant titled ‘Optimising intervention strategies to reduce the
burden of Group A Streptococcus in Aboriginal Communities’ (APP1098319).
7. Bibliography
References
[1] R. M. Anderson, R. M. May, and B. Anderson. Infectious Diseases of
Humans: Dynamics and Control. Wiley Online Library, 1992.
[2] R. M. Andrews, T. Kearns, C. Connors, C. Parker, K. Carville, B. J. Cur-
rie, and J. R. Carapetis. A Regional Initiative to Reduce Skin Infections
amongst Aboriginal Children Living in Remote Communities of the North-
ern Territory, Australia. Plos Neglected Tropical Diseases, 3(11), 2009.
[3] L. G. Arlian and D. L. Vyszenski-Moher. Life Cycle of Sarcoptes scabiei
var. canis. The Journal of Parasitology, 74(3):427–430, 1988.
[4] C. P. Bhunu, S. Mushayabasa, and T. G. Monera. Assessing the Impact of
Vaccination on Controlling the Spread of Human Scabies. ISRN Compu-
tational Biology, 2013, 2013.
15
[5] J. R. Carapetis, C. Connors, D. Yarmirr, V. Krause, and B. J. Currie. Suc-
cess of a scabies control program in an Australian Aboriginal community.
The Pediatric Infectious Disease Journal, 6:494–499, 1997.
[6] B. J. Currie and J. R. Carapetis. Skin infections and infestations in Abo-
riginal communities in northern Australia. Australasian Journal of Derma-
tology, 41:139–143, 2000.
[7] B. J. Currie and J. S. McCarthy. Permethrin and Ivermectin for Scabies.
The New England Journal of Medicine, 362(8):717–25, Feb. 2010.
[8] D. T. Gillespie. Exact stochastic simulation of coupled chemical reactions.
The Journal of Physical Chemistry, 81(25):2340–2361, 1977.
[9] S. J. Gilmore. Control Strategies for Endemic Childhood Scabies. PLOS
ONE, 6(1):e15990, 25-Jan-2011.
[10] P. J. Hotez, M. Alvarado, M.-G. Basa´n˜ez, I. Bolliger, R. Bourne, M. Boussi-
nesq, S. J. Brooker, A. S. Brown, G. Buckle, C. M. Budke, H. Carabin, L. E.
Coffeng, E. M. Fe`vre, T. Fu¨rst, Y. A. Halasa, R. Jasrasaria, N. E. Johns,
J. Keiser, C. H. King, R. Lozano, M. E. Murdoch, S. O’Hanlon, S. D. S.
Pion, R. L. Pullan, K. D. Ramaiah, T. Roberts, D. S. Shepard, J. L. Smith,
W. A. Stolk, E. A. Undurraga, J. Utzinger, M. Wang, C. J. L. Murray, and
M. Naghavi. The Global Burden of Disease Study 2010: Interpretation and
Implications for the Neglected Tropical Diseases. PLOS Neglected Tropical
Diseases, 8(7):e2865, 24-Jul-2014.
[11] T. Kearns, D. Clucas, C. Connors, B. J. Currie, J. R. Carapetis, and R. M.
Andrews. Clinic Attendances during the First 12 Months of Life for Abo-
riginal Children in Five Remote Communities of Northern Australia. PLoS
ONE, 8(3):1–5, 2013.
[12] T. M. Kearns, R. Speare, A. C. Cheng, J. McCarthy, J. R. Carapetis,
D. C. Holt, B. J. Currie, W. Page, J. Shield, R. Gundjirryirr, L. Bundhala,
E. Mulholland, M. Chatfield, and R. M. Andrews. Impact of an Ivermectin
Mass Drug Administration on Scabies Prevalence in a Remote Australian
Aboriginal Community. PLOS Negl Trop Dis, 9(10):e0004151, 30-Oct-2015.
[13] M. J. Keeling and P. Rohani. Modeling Infectious Diseases in Humans and
Animals. Princeton University Press, 2008.
[14] S. La Vincente, T. Kearns, C. Connors, S. Cameron, J. Carapetis, and
R. Andrews. Community Management of Endemic Scabies in Remote Abo-
riginal Communities of Northern Australia: Low Treatment Uptake and
High Ongoing Acquisition. PLOS Negl Trop Dis, 3(5):e444, 26-May-2009.
[15] J. S. Mccarthy, D. J. Kemp, S. F. Walton, and B. J. Currie. Scabies: More
than just an irritation. Postgraduate Medical Journal, 80(945):382–387,
2004.
16
[16] K. Mellanby. The development of symptoms, parasitic infection and im-
munity in human scabies. Parasitology, 35:197–206, 1944.
[17] L. Romani, J. Koroivueta, A. C. Steer, M. Kama, J. M. Kaldor, H. Wand,
M. Hamid, and M. J. Whitfeld. Scabies and impetigo prevalence and
risk factors in Fiji: A national survey. PLoS Neglected Tropical Diseases,
9:e0003452, 2015.
[18] L. Romani, A. C. Steer, M. J. Whitfeld, and J. M. Kaldor. Prevalence of
scabies and impetigo worldwide: A systematic review. The Lancet Infec-
tious Diseases, 15(8):960–967, 2015.
[19] L. Romani, M. J. Whitfeld, J. Koroivueta, M. Kama, H. Wand, L. Tikod-
uadua, M. Tuicakau, A. Koroi, R. Andrews, J. M. Kaldor, and A. C. Steer.
Mass Drug Administration for Scabies Control in a Population with En-
demic Disease. New England Journal of Medicine, 373(24):2305–2313, Dec.
2015.
[20] University of Sydney. Scabies. http://medent.usyd.edu.au/fact/scabies.html.
[21] V. Usha and T. V. G. Nair. A comparative study of oral ivermectin and top-
ical permethrin cream in the treatment of scabies. Journal of the American
Academy of Dermatology, 42(2):236–240, 2000.
[22] S. F. Walton, D. C. Holt, B. J. Currie, and D. J. Kemp. Scabies: New
Future for a Neglected Disease. volume 57, pages 309–376. Academic Press,
2004.
[23] L. Wong, B. Amega, R. Barker, C. Connors, M. E. Dulla, A. Ninnal, M. M.
Cumaiyi, L. Kolumboort, and B. J. Currie. Factors supporting sustainabil-
ity of a community-based scabies control program. Australasian Journal of
Dermatology, 43(4):274–277, 2002.
Appendix A. Transitions for model dynamics
Appendix A.1. Model A
The set of natural transitions is as follows: the infection transition is,
(XS , XI)→ (XS − 1, XI + 1) at rate βXS(XI +XIˆ), (A.1)
while the egg-laying transition is,
(XI , XIˆ)→ (XI − 1, XIˆ + 1) at rate γXI , (A.2)
and the egg-hatching transition (post-treatment) is,
(X
Gˆ
, XI)→ (XGˆ − 1, XI + 1) at rate σXGˆ. (A.3)
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The set of treatment transitions is,
(X
Iˆ
, X
Gˆ
)→ (X
Iˆ
− 1, X
Gˆ
+ 1) at rate τX
Iˆ
, (A.4)
when an individual has adult mites and eggs on them, and
(XI , XS)→ (XI − 1, XS + 1) at rate τXI , (A.5)
for an individual carrying no eggs.
Appendix A.2. Model B
The set of natural transitions is as follows: the infection transition is,
(XS , XI)→ (XS − 1, XI + 1) at rate βXS(XI +XIˆ), (A.6)
while the egg-laying transition is,
(XI , XIˆ)→ (XI − 1, XIˆ + 1) at rate γXI , (A.7)
and the egg-hatching transition (post-treatment) is,
(X
Gˆ
, X
Yˆ
)→ (X
Gˆ
− 1, X
Yˆ
+ 1) at rate σX
Gˆ
. (A.8)
The transition where the last egg hatches, and only young mites remain is,
(X
Yˆ
, XY )→ (XYˆ − 1, XY + 1) at rate ρXYˆ , (A.9)
and the maturation of the first mite is,
(XY , XI)→ (XY − 1, XI + 1) at rate δXY . (A.10)
The set of treatment transitions is,
(X
Iˆ
, X
Gˆ
)→ (X
Iˆ
− 1, X
Gˆ
+ 1) at rate τX
Iˆ
, (A.11)
when an individual has adult mites and eggs on them,
(X
Yˆ
, X
Gˆ
)→ (X
Yˆ
− 1, X
Gˆ
+ 1) at rate τX
Yˆ
, (A.12)
for when an individual has young mites and eggs and
(XI , XS)→ (XI − 1, XS + 1) at rate τXI , (A.13)
for an individual carrying no eggs.
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Appendix B. Mean Field Approximation
The full set of ordinary differential equations which make up the mean field
approximation with non-ovicidal treatment is,
x˙S = −βxSI(t) + τxIA + µ(1− xS) + ωxIA (t),
x˙IA = βxSI(t)− (γ + τ + µ)xIA − ωxIA (t),
x˙
IˆA
= γxIA − (ψ + τ + µ)xIˆA − ωxIˆA
(t),
x˙
Iˆ
= ψx
IˆA
− (τ + µ)x
Iˆ
− ωx
Iˆ
(t),
x˙
Gˆ
= τ(x
IˆA
+ x
Iˆ
+ x
Yˆ
+ x
Iˆc
2
+ x
Iˆ2
)− (σ + µ)x
Gˆ
+ ωxIA (t) + ωxIˆ (t) + ωxYˆ (t) + ωxIˆc
2
(t) + ωx
Iˆ2
(t),
x˙
Yˆ
= σx
Gˆ
− (ρ+ τ + µ)x
Yˆ
− ωx
Yˆ
(t),
x˙Y = ρxYˆ − (δ + τ + µ)xY − ωxY (t),
x˙M = δxY − (α+ τ + µ)xM − ωxM (t),
x˙S2 = τ(xY + xM + xIc2 + xI2)− φβxS2 I(t)− µxS2 + ωxY + ωxIc
2
(t) + ωxI2 (t),
x˙Ic
2
= αxM − (γ + τ + µ)xIc
2
− ωxIc
2
(t),
x˙
Iˆc
2
= γxIc
2
− (τ + µ)x
Iˆc
2
− ωx
Iˆc
2
(t),
x˙I2 = φβxS2I(t) − (γ + τ + µ)xI2 − ωxI2 (t),
x˙
Iˆ2
= γxI2 − (τ + µ)xIˆ2 − ωxIˆ2
(t),
where,
I(t) = xIA + xIˆA + xIˆ + xI
c
2
+ x
Iˆc
2
+ xI2 + xIˆ2 ,
is the proportion of infected individuals at time t.
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For ovicidal treatment, the mean field approximation is,
x˙S = −βxSI(t) + τxIA + µ(1− xS) + ωxIA (t),
x˙IA = βxSI(t)− (γ + τ + µ)xIA − ωxIA (t),
x˙
IˆA
= γxIA − (ψ + τ + µ)xIˆA − ωxIˆA
(t),
x˙
Iˆ
= ψx
IˆA
− (τ + µ)x
Iˆ
− ωx
Iˆ
(t),
x˙
Gˆ
= (σ + µ)x
Gˆ
,
x˙
Yˆ
= σx
Gˆ
− (ρ+ τ + µ)x
Yˆ
− ωx
Yˆ
(t),
x˙Y = ρxYˆ − (δ + τ + µ)xY − ωxY (t),
x˙M = δxY − (α+ τ + µ)xM − ωxM (t),
x˙S2 = τ(xIˆA + xIˆ + xY + xM + xYˆ + xI
c
2
+ x
Iˆc
2
+ xI2 + xIˆ2)− φβxS2 I(t)− µxS2 ,
+ ωxIA (t) + ωxIˆ (t) + ωxY + ωxYˆ (t) + +ωxIc2
(t) + ωx
Iˆc
2
(t) + ωxI2 (t) + ωxIˆ2
(t)
x˙Ic
2
= δxY − (γ + τ + µ)xIc
2
− ωxIc
2
(t),
x˙
Iˆc
2
= γxIc
2
− (τ + µ)x
Iˆc
2
− ωx
Iˆc
2
(t),
x˙I2 = φβxS2I(t)− (γ + τ + µ)xI2 − ωxI2 (t),
x˙
Iˆ2
= γxI2 − (τ + µ)xIˆ2 − ωxIˆ2
(t)
Appendix C. Determining probability of contact and infectiousness,
and rate of treatment
The mean time to first infection for scabies is 225 days [11]. We utilise the
common approximation that the force of infection, λ is equal to the inverse of
the mean time to first infection [13]. That is,
λ =
1
225
.
We utilise the relationship,
λ = βI,
and take the prevalence of scabies to be I = 0.28 [18] for the purposes of this
study. This gives,
β =
λ
I
=
1
63
.
Considering the system, x(t), at equilibrium, and all parameters except τ
and φ fixed and that there is no natural recovery in this model, the rate of
new infections is equal to the combined rate of treatment and death out of each
infected state. As the death rate, µ, is much smaller than the per-individual
treatment rate, τ . it follows that,
total rate of new infections = λ(xS + φxS2) + σxGˆ = total rate of treatment.
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Figure C.9: Background treatment rate, τ , as a function of the reduction in susceptibility, φ.
The total rate of treatment is,
total rate of treatment = τ(1 − (xS + xS2 + xGˆ)),
and so,
λ(xS + φxS2) + σxGˆ = τ(1 − (xS + xS2 + xGˆ)). (C.1)
We assume the prevalence of scabies to be 0.28 [18]. That is,
1− (xS + xS2 + xGˆ) = 0.28.
Thus,
0.28τ = λ(xS + φxS2 ) + σxGˆ. (C.2)
with which we cannot uniquely determine τ or φ. However, as φ is bounded
between 0 and 1, we can explore the possible range for τ by solving Equation
(C.2) numerically. This is shown in Figure C.9.
Appendix D. Investigation of relative susceptibility to secondary in-
fections
Little is known about the level of relative susceptibility to secondary infec-
tions for scabies infections. The human infection study for scabies [16] does note
an approximately 50% decreased parasite load for individuals experiencing sec-
ondary infections, but does not investigate the impact this has on transmission.
Here, we consider the entire range of possible values for the relative susceptibil-
ity, φ, and measure the influence of this on the probability of eradication. Figure
D.10 shows the estimated probability of eradication following some number of
MDA’s under a non-ovicidal treatment scheme in a population size of N = 2000.
We observe that when individuals are almost immune to secondary infections,
that is when φ is small, the eradication probability decreases. This decrease is
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Figure D.10: Mean, x¯, of 1000 simulations of the Markov chain, X(t), which experienced
die-out for varying numbers of successive optimally timed non-ovicidal MDA treatments and
a varying relative susceptibility to secondary infections, φ, with all other parameter values as
in Table 1 and a population size of N = 2000.
caused by the small rate of background treatment, τ , that is required in the
model to maintain the correct prevalence and age of first infection as discussed
in Appendix C. However, it can be seen that the probability of eradication
is relatively unchanged for a fixed number of MDA’s beyond φ = 0.2. This
suggests that the conclusions from this model are robust with respect to the
relative susceptibility, φ (and thus the background treatment rate, τ), unless
the relative susceptibility is particularly low.
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